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 expression in 
prostate cancer. The analysis included 32 
cases of prostate cancer, nine of prostatic 
intraepithelial neoplasia (PIN) and 19 normal 
prostates. Samples were scored for the 
percentage of stained glands and intensity 
of staining (from 0 to 3). Each sample was 
assigned a composite score generated by 








 expression in prostate cancer than in 










in prostate cancer cell lines (LNCaP, 22Rv1, 
PC3, DuPro) was detected using quantitative 




 and its signalling partners FAK and PXN 
was detected in human tissue. Comparing 
normal with cancer samples, there was a 2.1-





















































 and its related signalling partners are 
up-regulated in prostate cancer, and support 
further investigation into the role of the FYN 




FYN, SRC, prostate cancer, paxillin, FAK
Study Type – Aetiology (case control)








, a member 
of the SRC family of kinases (SFKs), is 





functionally distinct from other SFKs, and 
interacts with FAK and paxillin (PXN), 




Through data-mining in Oncomine (http://
www.oncomine.org), cell-line profiling with 
immunoblotting, quantitative reverse 
transcription and polymerase chain reaction 




Prostate cancer is the most common cancer 




200 000 new cases of cancer diagnosed in 
2008 [1]. While many men have disease that is 
either amenable to local therapy (surgery 
or radiation), many will develop metastatic 
disease. It is this population that is at risk of 
morbidity and death from both the disease 
and treatment-related side-effects, such as 
osteoporosis or cardiovascular events. Despite 




30 000 men are 
expected to die in 2008 from this disease. 
These figures have driven an aggressive 
search for promising molecular targets in 
prostate cancer. Castration is a highly 
effective and widely used therapy for men 
with this disease, but most patients will 
progress to a castration-resistant state. This 
progression is associated with increased 
morbidity and mortality rates. At present only 
docetaxel-based chemotherapy has been 
shown to extend survival for this population 
of patients. Thus, many therapeutic targets 
have been proposed and explored. Tyrosine 
kinases are known to be dysregulated in 
prostate cancer, and as clinically useable 
agents have become available, several of 
these have been studied in prostate cancer, 
including the epidermal growth factor (EGF) 
receptor, vascular endothelial growth factor 
receptor, and B/C raf-kinase, none of which 
have yet shown significant clinical efficacy. 
Gene expression profiling of non-receptor 
tyrosine kinases in prostate cancer has 
shown that the SRC family is particularly 
dysregulated in prostate cancer [2].
The SRC-family of kinases (SFKs) is one of 
the most studied families of proteins in 
cancer biology. Since the identification and 
description of the pp60c-SRC, eight other 
proteins sharing significant structural 
homology have been identified. The SFKs have 
long been recognized as overexpressed in 
several cancers, including prostate cancer. 
Each member is distinguished by a unique 
region that specifies its respective binding 
partners and hence function.
FYN is a 59-kDa member of this family and 
was one of the first members to be identified. 




 is located on 
chromosome 6q21. The most abundant 
transcript encodes a protein composed of 537 
amino acids with a structure similar to the 
other SFKs, except for the unique region. Like 
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other SFKs, FYN is a non-receptor tyrosine 
kinase that functions downstream of several 
cell-surface receptors. Its best characterized 
functions are in neuronal development 
and T-cell signalling [3], but FYN also 
induces morphogenic transformation when 
overexpressed [4]. FYN is recognized as an 
important mediator of mitogenic signals and 
as a regulator of cell cycle entry, growth and 
proliferation. It is also known to mediate 
integrin interactions and hence cell-cell 
adhesion. FYN is known to interact with 
several molecular signals including FAK and 
paxillin (PXN) [5,6] which might account for 
the described morphogenic transformation 
and possibly lend insight into its role in 
cancer.
In this report we present the first series of 
studies showing the specific importance of 
FYN in prostate cancer. Our approach used a 
combination of both data-mining and tissue 
microarray (TMA) immunohistochemical (IHC) 









 in prostate cancer was 
queried using the Oncomine database (http://
www.oncomine.org) in February 2008. This is 
a publicly available database summarizing 
gene-chip experiments across tissue types [7]. 
Oncomine provides an infrastructure of data-
mining tools to query genes and data sets 
of interest, and to meta-analyse groups of 
studies. This database was queried for gene 
expression data for 
 







. Studies were 
included if they compared primary prostate 
cancers to any of the following: normal or 
benign epithelium, metastatic prostate 
cancer, prostatic intraepithelial neoplasia 





 values presented are extracted 
directly from the Oncomine analysis and have 
not been repeated manually.
All cell lines used were obtained from the 
American Type Culture Collection (Manassas, 
VA, USA). Lines used included standard 
prostate cancer cell lines: LNCaP, CWR22Rv1, 
PC3, and DuPro; U87 are malignant astrocytes 
that were used as a positive control for 
FYN [8]. Cells were grown according to the 
supplier’s recommendations, in RPMI 1640 
with 10% fetal calf serum and penicillin/
streptomycin supplement.
All human tissue samples used in the 
study were obtained from the University 
of Michigan through an interSPORE 
collaboration. The use of tissue complied with 
an institutional review board-approved 
protocol requiring that all samples were kept 
anonymous to the primary investigational 
team.
Tissue was analysed in the form of a TMA, 
the fabrication of which was described by 
the University of Michigan group elsewhere 
[9]. In short, the initial TMA used contained 
120 patient specimens planned to have 
triplicate representation on the TMA; each 
element was 0.6 mm in diameter. Tissue 
samples included primary tumour from 
patients with prostate cancer, with 
Gleason 6–9 disease, metastatic tumour 
sites, PIN, proliferative inflammatory atrophy, 
BPH, prostatic stroma and normal prostate 
tissue. The identity of patients was withheld 
from the primary analytical group. Normal 
glands present on the TMA were taken 
from patients who had prostatectomy or 
cystectomy. A patient’s sample was only 
considered useable if represented at least 
twice on the array.
Commercially available antibodies were used 
for all immunoblotting and IHC studies. Anti-
FYN was obtained from Millipore (Burlington, 
MA, USA); Anti-FAK was obtained from 
Invitrogen (Carlsbad, CA, USA); and anti-PXN 
antibody 5H11 was obtained from Biosource 
(Invitrogen).
For protein extraction and Western blotting, 
monolayer cells were grown to 80% 
confluence then washed in ice-cold PBS. 
Protein lysates were prepared using lysis 





glycerophosphate, 2 mmol/L DDT, 1 mmol/L 
EDTA, 150 mmol/L NaCl, 0.5 mmol/L NaF, 





phenylmethylsulphonyl fluoride, 1% 
Triton X-100 w/v, 70 units/mL aprotinin, 
and one Complete Protease Inhibitor 
Cocktail tablet, Roche, Basel, Switzerland). 
Cells were scraped and placed on ice after 
being passed through a 27-G needle and 





was quantified using the bicinchoninic acid 





g of protein were subjected to SDS-PAGE 
and transferred to a HyBond Enhanced 
Chemiluminescence nitrocellulose membrane 
(GE Healthcare Biosciences, Piscataway, NJ, 
USA).
For Western blotting, membranes were 




C overnight in TBS-Tween plus 
5% (w/v) non-fat dried milk. After incubation 
with each antibody diluted in blocking 
solution for 1 h, the membrane was washed 
for 10 min in blocking solution and then 
washed six times for 5 min each in TBS-T. 
The horseradish peroxidase-conjugated 
secondary antibody was detected using 
the Super Signal West Femto Maximum 
Sensitivity Chemiluminescence Substrate 
(Pierce) according to the manufacturer’s 
directions. Probed membranes were 
stripped using Pierce Restore Western 
Blot Stripping Buffer, washed in TBS-T, and 
blocked overnight before re-probing. The 
dilutions of antibodies were: anti-FYN 1:1000, 
anti FAK 1:1000, anti-PXN 1:500. As a loading 
control, membranes were probed for actin 
followed by incubation with a goal antimouse 
IgM-peroxidase-conjugated secondary 
antibody (Oncogene Research, Uniondale, 
NY, USA; 1:20 000 and 1:40 000 dilutions 
of primary and secondary antibodies, 
respectively).
RNA from cell lines was extracted using 
an RNAqueous kit (Ambion, Auton, TX, 
USA) according to the manufacturer’s 













 were prepared by Integrated DNA 
Technologies (Coralville, IA, USA). The left 
primer was: ATG GAA ACA CAA AAG TAG CCA 
TAA A; and the right primer: TCT GTG AGT AAG 
ATT CCA AAA GAC C. Data were calibrated to 
the expression of glyceraldehyde phosphate 
dehydrogenase. Quantitative PCR was 
performed using SYBR Green dye on an ABI 
7700 (Applied Biosystems, Foster City, CA, 
USA).
For IHC, stained TMA sections were analysed 
by a dedicated urological pathologist (H.A.A.) 
while unaware of sample origin. Results were 
reported semiquantitatively on a scale of 0–3 
for intensity, where 0 was negative, 1 was 
weak, 2 was moderate and 3 was strong. 
The percentage of tumour staining was 
reported as 0–100% in increments of 10%. 
A composite score was formed using the 
product of the intensity and percentage of 
glands staining. Human breast cancer tissue 
was used as a positive staining control, as 
recommended by the manufacturer [10]. 
Human leiomyomas were used as a negative 
control. FYN was stained using an antibody 
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 was used to 
compare expression levels (based on the 
percentage staining or the composite score) 
across groups. The equal-variance assumption 
was verified using Bartlett’s test [11]. Post-
hoc pair-wise comparisons were performed 
with a Bonferroni adjustment for multiple 
comparisons. The Kruskal–Wallis test was 
used to compare the ordinal staining intensity 
score. Also, a nonparametric trend test 
[12] was used for further examination of 
expression levels across the naturally ordered 
groups. The mean of the duplicate or triplicate 
samples for each subject was used in the 













To identify SFKs for analysis, we reviewed 
available studies in the Oncomine database. 
On comparing malignant with normal 
prostate epithelium, the member of this 
family that arose as the most consistently and 




, which was 








 0.001) [13]. 
There was little or no change in the remainder 













 further increased 
by 10 times in the transition from localized to 





) or showed 










FYN was chosen for further investigation as it 
was identified as the most up-regulated SFK 
in prostate cancer. Given the homology of 
the various members of the family, several 
antibodies were tested and eliminated 
on the basis of sensitivity and specificity 
(supplemental data, Table 1). The expression 
of FYN was evaluated in standard prostate 
cancer cell lines (Fig. 1a, top). The U87 cell line 
was used as a positive control, as malignant 
astrocytes are known to express FYN [8]. 
Findings were verified by quantitative 
reverse transcription-PCR (Fig. 1b). There was 
expression of FYN RNA and protein in all 
tested cell lines. FYN was not expressed in 
human leiomyoma samples (immunoblot-
verified negative control; data not shown).
We then verified the Oncomine findings in 
human tissue samples using IHC analysis 
of a TMA obtained from the University of 
Michigan, that contained samples of normal 
prostate, PIN and prostate cancer. There were 
86 useable patient samples for the FYN 
analysis (Table 2). We stained the TMA for 
total FYN (Fig. 2) and analysed by generating a 
composite score from the percentage of 
tumour cells staining and intensity. Several 
candidate antibodies were tested and 
discarded (Table 1) if they failed to 
show sensitivity and specificity to tumour 
tissues and expected positive control (e.g. 
lymphocytes) or if the pattern of staining did 
not correlate with the biology of FYN. For 




Primary FYN antibodies tested, with the results
 
Manufacturer, id# Results
Cell Signalling, #4023 Several high molecular weight bands seen in addition to FYN




59 kDa, but on IHC predominantly nuclear staining.
Upstate, 04-353 Single band at 59 kDa. Cytoplasmic staining on IHC.
Chemicon, MAB8900 No bands seen
Santa Cruz, SC-16 Strong band at 59 kDa but several high molecular weight bands,




The patient demographics 
for FYN analysis
 
Variable N or median (range)







































Expression of FYN and signalling partners FAK and PXN in prostate cancer cell lines shown by (a) 
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nuclear staining in all samples was declared to 
be erroneous.
The median (range) composite score for 
cancer specimens was 200 (23–300); scores 
did not correlate significantly with Gleason 
score (data not shown). Of 32 tumour 
samples, 19 (59%) had scores of 200–300. For 
normal epithelium the median (range) score 
was 93 (7–160) and for PIN, 120 (45–220). 
Figure 3 shows the distribution of composite 
scores for FYN. Staining of FYN was strong in 









 0.001 for the overall 
comparison). Differences in expression 
between normal and cancer and PIN and 
cancer were both statistically significant, 
based on the composite score. Specifically, 
there was a 2.1 times greater median 









 0.001) and a 1.7 times greater score 









Furthermore, there was evidence for 
increasing expression levels across these three 








 0.001 for trend). 
Ten metastatic tumours were represented 
from various sites (lymph node, lung, liver), 
with a median (range) scores of 102 (10–290). 
With so few samples it was not possible to 
confirm or deny the absence of a trend in FYN 
expression, but this merits further study.
As FYN interacts with several regulators of 
cellular morphology and attachment, cell lines 
and human tissue samples were re-examined 
for FAK and PXN. Immunoblotting showed co-
expression of FAK and PXN with FYN (Fig. 1a, 
middle, bottom). Both were most highly 
expressed in the castrate-resistant cell lines 
(PC3 and DuPro) consistent with the data-
mining presented earlier. Castrate-sensitive 
lines (LNCaP and 22Rv1) showed expression 
of both FAK and PXN but at a much lower 
level.
To extend the studies to clinical material, FAK 
and PXN expression was evaluated on the 
TMA. Representative sections stained for FAK 
and PXN are shown in Fig. 2 (middle and 
bottom). There were 35 useable tumour 
samples for FAK and 22 for PXN analysis. 
Our findings for the TMA population are 
represented graphically in Fig. 3 (middle and 
bottom).
The median (range) FAK score was 180 (40–
300) in tumour samples. There was a tendency 
for higher Gleason tumours to have higher 
FAK scores, but this association was not 
statistically significant. Twelve of 35 (34%) 
samples had scores of 200–300. In normal 
epithelium the FAK score was 107 (53–253) 
and in PIN it was 113 (35–167). In the final 
analysis, there was 1.7 times greater FAK 













Expression of FYN, FAK, and PXN in malignant and non-malignant prostate epithelium. Representative 




Plots of (A) FYN (B) FAK and (C) PXN 
staining in malignant vs non-malignant tissue 





 percentage of glandular cells staining) 




-axis. The median is plotted with 
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 0.01). The score in metastatic lesions was 
140 (57–290).
The median (range) PXN score for tumour 
samples wa 155 (25–300), with no clear 
relationship with Gleason score. Only two of 
22 (9%) useable specimens had PXN scores of 
200–300 (285, 300). The score in normal 
prostate samples was 77 (25–160) and that 
for PIN 72 (40–150), but only four samples 
were available for analysis due to poor 
transfer. There was a doubling of PXN staining 









 0.05). The few PIN specimens precluded 
any comparisons between PIN and cancer. 
These data indicate an up-regulation of FAK 
and PXN in prostate cancer compared with 





Through a combination of data-mining, 
immunoblotting and IHC we showed up-
regulation of FYN, a particular member of the 
SRC family of kinases, in prostate cancer. 
The initial Oncomine queries suggested 
particularly high overexpression of FYN in 
cancer compared with normal prostate (non-





malignancy (PIN). There was expression of 
FYN in both a panel of prostate cancer cell 
lines and human tissue samples. This was 
accompanied by expression of the FYN 
signalling partners FAK and PXN, factors 
known to regulate cellular motility and 
metastasis. There were discrepancies 
between the magnitude of FYN measured by 
quantitative RT-PCR and immunoblot, but 
there are frequent published reports of 
discrepancies between RNA and protein 
expression. Specifically, FYN has been shown 
to undergo post-transcriptional modification 
which might affect protein expression [15].
The data-mining further suggested that this 
up-regulation of expression is specific to FYN 
and not the other members of the SRC family. 
While the SRC kinases share similarities in 
sequence and structure they have differences 
that might be germane to the development of 
SFK-directed therapies. Most SFK-directed 
research in cancer has been aimed at the 
expression of c-SRC. To date, the role of FYN 





2300 citations in Pubmed referencing 





200 studies mentioning FYN 
expression in various cancer models, only a 
few of which specifically focus on FYN 
biology. FYN has been implicated as a 
mediator of EGF-driven transformation of 
JB6 cells [16]. In breast cancer, FYN expression 
was shown to correlate with poorer survival, 
and correlated with FAK up-regulation [17]. 
In haematological malignancies, FYN has 
been identified as a putative target for 
treating BCR-ABL-expressing adult acute 
lymphoblastic leukaemia, due to the centrality 
of its relationship to several important 
molecular signals suspected to drive the 
proliferation of malignant leukaemic blasts 





 antiproliferative activity in 
acute lymphoblastic leukaemia [19]. In other 
solid tumours such as melanoma, FYN has 
been implicated as a mediator of integrin 
signalling, and thus appears to regulate 
metastatic potential [20].





expression in prostate cancer [21]. This group 
recognized an allelic imbalance at 6q14–22 
and sought to identify tumour suppressors 




 as a potential tumour suppressor, noting 
that the highest levels of FYN were in BPH, 
compared with malignant tissues which 
showed little or no FYN expression. While the 
results appear to be contradictory, the present 
study does not specifically address the role of 
FYN in BPH. Members of the SRC family are 
known to have several different roles in 
various cellular contexts, and thus it is entirely 
possible that in one biochemical context FYN 
serves as a tumour suppressor, while in the 
altered biochemical landscape of neoplastic 
transformation (i.e. in the change from pre-
invasive, to invasive, then again to metastatic) 
that FYN serves another role altogether. 
Further studies will be needed to show the 




 in these various 
settings. This type of dynamic signalling 
behaviour has been seen with other molecular 
targets (including proposed tumour 





 [21] reported an 
immunohistochemical analysis similar to that 
presented here. The present results agree, 
insofar as there was expression of FYN in 
normal and hyperplastic epithelium. What 
requires reconciliation is the absence of FYN 





 In the present study, samples 
from all 32 patients with prostate cancer 
showed high levels of FYN expression. This 
might be the result of technical issues, such as 
the choice of antibody in the IHC results, as 
we found during our screening. Finally the 




 suggested that by 





 in tumour samples from 
patients. The approach taken made use of 
whole-tissue homogenates, making the 
epithelial cell content difficult to control. This 
is especially important given the congruent 
findings of absent FYN expression in the 
stromal compartment.
FYN is positioned downstream of several 
important cell-surface receptors and 
upstream of several cellular signals important 
for prostate cancer progression. Like other 
SRC family members, it is known to mediate 
some cell-shape and migration behaviours. As 
such, its interactions with mediators of cell 
shape and motility were important factors to 
study. Our data also suggest that there is an 
accompanying up-regulation of FAK and PXN, 
both of which are important regulators of cell 
shape and interactions with other cells, and 
the extracellular matrix. Both FAK [23–26] and 
PXN [26,27] have been recognized as crucial 
to motility, and thus invasion, which are 
cellular processes required for metastatic 
competence and acquisition of the metastatic 
phenotype.
The expression of FAK and PXN in prostate 
cancer have been correlated with disease 
progression [26,28]. FAK has been shown to 
play a role in prostate cancer metastasis by 
disrupting integrin-mediated signalling from 
the extracellular matrix. The invasive ability of 
DU145 cells on fibronectin was inhibited by 
silencing FAK expression via siRNA [29]. SRC 
kinases have been implicated as potential 
means of modulating FAK activity in prostate 
cancer and SRC inhibitors have been shown 
to down-regulate FAK activation [23]. 
Overexpression of leupaxin, a member of the 
PXN family, was shown to cause an increase in 
cellular motility in PC3 cells [30]. Again, SRC 
kinase inhibitors have been shown to down-
regulate the activation of PXN, which in turn 
results in decreased cellular motility [5]. Given 
the overexpression of FYN noted here, and the 
nonspecific nature of most SFK inhibitors, it is 
likely that the bulk of this effect is mediated 
by FYN.
These findings gain translational relevance 
with the introduction of SRC-family 
inhibitors into clinical practice. Dasatinib is 
commercially available for treating chronic 
myelogenous leukaemia, and is currently 
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being evaluated as a treatment for castrate-
resistant prostate cancer. Other agents such 
as AZD0530 and bosutinib are currently in 
clinical development, with a host of others to 
follow. AZD0530, a potent SRC/ABL inhibitor, 
has been shown to have a potent effect on 
cellular motility which is SFK-mediated [31]. 
While labelled as inhibitors of c-SRC, these 
drugs are known to have various inhibitor 
effects on cellular tyrosine kinases, including 
FYN. Furthermore, several inhibitors of 
both FAK and PXN are currently under 
development. This raises the potential for 
combined approaches with these signal-
transduction inhibitors in a vertical fashion, 
which might have potent effects on cellular 
motility and invasion. If relatively nontoxic, 
such an approach might be an effective 
treatment after definitive local therapy in 
concert with or after castration.
In conclusion, our findings show a statistically 
significant up-regulation of FYN and its 
signalling partners FAK and PXN through 
data-mining, immunoblotting and IHC. It is 
hoped that further understanding of the role 
of FYN in prostate cancer development and 
progression might provide insights into how 
FYN-inhibitory agents should be used in the 
clinic. Given our findings, we think that FYN is 
a promising molecular target for cancer 
therapeutics.
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